Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
TriSalus Life Sciences Inc. (TLSIW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: TLSIW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -54.53% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.47 | 52 Weeks Range 0.42 - 2.25 | Updated Date 06/10/2025 |
52 Weeks Range 0.42 - 2.25 | Updated Date 06/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -84.67% | Operating Margin (TTM) -79.95% |
Management Effectiveness
Return on Assets (TTM) -85.52% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 29370602 |
Shares Outstanding - | Shares Floating 29370602 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
TriSalus Life Sciences Inc.
Company Overview
History and Background
TriSalus Life Sciences Inc. is a commercial-stage oncology company dedicated to developing and delivering innovative therapies for liver and pancreatic tumors. The company focuses on leveraging its proprietary pressure-enabled drug delivery technology to improve outcomes for patients with these difficult-to-treat cancers. Founded in 2009, TriSalus has achieved significant milestones including FDA clearances for its products and progress in clinical trials.
Core Business Areas
- Pressure-Enabled Drug Delivery (PEDD): Develops and commercializes devices for direct administration of therapeutics into solid tumors, particularly in the liver and pancreas. This targeted delivery aims to overcome physiological barriers and enhance drug penetration.
- Immunotherapeutic Development: Focuses on developing immunotherapeutic approaches to stimulate the patient's immune system to fight cancer. This is often combined with PEDD to maximize therapeutic effect.
Leadership and Structure
TriSalus Life Sciences Inc. is led by a team of experienced executives with expertise in oncology, drug delivery, and medical device development. Details on the specific team and organizational structure can be found on their investor relations website.
Top Products and Market Share
Key Offerings
- TriNav Microcatheter: A microcatheter used for pressure-enabled drug delivery directly to liver tumors. It's designed to improve drug penetration and therapeutic efficacy. TriSalus has been approved by the FDA for this process. Key competitors are Boston Scientific (BSX) and Medtronic (MDT). Revenue data is available in investor filings, it is not easily available and depends on sales.
- CellWorks Enterprise: An AI-Driven companion diagnostic which predicts personalized drug responses for cancer patients. Key competitors are Tempus Labs and Caris Life Sciences. Revenue data is available in investor filings, it is not easily available and depends on sales.
Market Dynamics
Industry Overview
The oncology market is a large and growing market driven by increasing cancer incidence and advancements in treatment options. Targeted drug delivery and immunotherapy are key areas of innovation. The interventional oncology space is expected to see significant growth due to minimally invasive procedures becoming increasingly popular.
Positioning
TriSalus is positioned as an innovator in the interventional oncology space, focusing on improving outcomes for patients with liver and pancreatic tumors through its proprietary PEDD technology and immunotherapeutic approaches. Their competitive advantage lies in their novel drug delivery system and clinical data supporting its efficacy.
Total Addressable Market (TAM)
The TAM for liver and pancreatic cancer treatments is substantial, estimated to be in the billions of dollars annually. TriSalus is focused on capturing a portion of this market through its innovative products and therapies. Their TAM will continue to grow with positive clinical trials and approvals.
Upturn SWOT Analysis
Strengths
- Proprietary pressure-enabled drug delivery technology
- Focus on difficult-to-treat liver and pancreatic tumors
- FDA-cleared products
- Growing clinical data supporting efficacy
- Experienced management team
Weaknesses
- Limited commercial infrastructure compared to larger competitors
- Dependence on successful clinical trial outcomes
- Relatively small market capitalization
- Cash flow management challenges
Opportunities
- Expansion into new tumor types
- Partnerships with pharmaceutical companies
- Positive clinical trial results
- Increased adoption of interventional oncology procedures
- FDA approvals for new products
Threats
- Competition from larger medical device and pharmaceutical companies
- Regulatory hurdles
- Reimbursement challenges
- Unfavorable clinical trial results
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- BSX
- MDT
- Varian Medical Systems (VAR) (now part of Siemens Healthineers)
- Sirtex Medical (acquired by Varian)
Competitive Landscape
TriSalus Life Sciences Inc. competes with larger, more established medical device and pharmaceutical companies. Its advantage lies in its innovative PEDD technology and focus on liver and pancreatic tumors. However, it faces challenges related to commercial scale and financial resources.
Growth Trajectory and Initiatives
Historical Growth: TriSalus Life Sciences Inc.'s historical growth can be assessed by analyzing its revenue and product adoption trends over the past few years. Consult their financial statements for specific data.
Future Projections: Future growth projections can be obtained from analyst reports and company presentations. These estimates often depend on clinical trial outcomes and regulatory approvals.
Recent Initiatives: Recent strategic initiatives may include new product launches, clinical trial announcements, partnerships, and acquisitions.
Summary
TriSalus Life Sciences Inc. is a niche oncology company with promising PEDD technology, but faces challenges of commercialization and competing with larger firms. Successful clinical trials and partnerships are key to its growth. Its financial performance is currently weak, requiring close monitoring of cash flow. Positive regulatory decisions and market adoption will be essential for future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- TriSalus Life Sciences Inc. investor relations website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and does not constitute financial advice. Market conditions and company performance can change rapidly. Conduct thorough research before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About TriSalus Life Sciences Inc.
Exchange NASDAQ | Headquaters Westminster, CO, United States | ||
IPO Launch date 2023-08-11 | CEO, President & Director Ms. Mary T. Szela B.S.N., M.B.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 110 | Website https://trisaluslifesci.com |
Full time employees 110 | Website https://trisaluslifesci.com | ||
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. The company was founded in 2009 and is headquartered in Westminster, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.